Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, has announced a proposed public offering of common stock and warrants. The offering will be managed by A.G.P./Alliance Global Partners as the sole placement agent.
The company plans to use the proceeds to fund research and development activities and for working capital purposes. The securities will be offered under an effective shelf registration statement filed with the SEC. The final size, terms, and completion of the offering are subject to market conditions.
Reviva Pharmaceuticals (NASDAQ: RVPH), un'azienda farmaceutica in fase avanzata focalizzata su malattie del sistema nervoso centrale, infiammatorie e cardiometaboliche, ha annunciato una proposta di offerta pubblica di azioni ordinarie e warrant. L'offerta sarà gestita da A.G.P./Alliance Global Partners come unico agente di collocamento.
L'azienda prevede di utilizzare i proventi per finanziare attività di ricerca e sviluppo e per scopi di capitale circolante. I titoli saranno offerti nell'ambito di una dichiarazione di registrazione a scaffale efficace depositata presso la SEC. La dimensione finale, i termini e il completamento dell'offerta dipenderanno dalle condizioni di mercato.
Reviva Pharmaceuticals (NASDAQ: RVPH), una empresa farmacéutica en etapa avanzada enfocada en enfermedades del sistema nervioso central, inflamatorias y cardiometabólicas, ha anunciado una propuesta de oferta pública de acciones comunes y warrants. La oferta será gestionada por A.G.P./Alliance Global Partners como único agente colocador.
La compañía planea usar los ingresos para financiar actividades de investigación y desarrollo y para propósitos de capital de trabajo. Los valores se ofrecerán bajo una declaración de registro en estantería efectiva presentada ante la SEC. El tamaño final, los términos y la finalización de la oferta están sujetos a las condiciones del mercado.
Reviva Pharmaceuticals (NASDAQ: RVPH)는 중추신경계, 염증 및 심장대사 질환에 중점을 둔 후기 단계 제약회사로, 보통주와 워런트에 대한 공개 제안을 발표했습니다. 이 제안은 A.G.P./Alliance Global Partners가 단독 배정 대행사로 관리합니다.
회사는 조달된 자금을 연구개발 활동 자금 및 운전자본 용도로 사용할 계획입니다. 증권은 SEC에 제출된 유효한 선반 등록 성명서에 따라 제공됩니다. 최종 규모, 조건 및 제안 완료는 시장 상황에 따라 달라질 수 있습니다.
Reviva Pharmaceuticals (NASDAQ: RVPH), une société pharmaceutique en phase avancée spécialisée dans les maladies du système nerveux central, inflammatoires et cardiométaboliques, a annoncé une offre publique proposée d'actions ordinaires et de bons de souscription. L'offre sera gérée par A.G.P./Alliance Global Partners en tant qu'agent unique de placement.
La société prévoit d'utiliser les fonds pour financer les activités de recherche et développement et pour des besoins en fonds de roulement. Les titres seront proposés dans le cadre d'une déclaration d'enregistrement en étagère effective déposée auprès de la SEC. La taille finale, les modalités et la réalisation de l'offre dépendent des conditions du marché.
Reviva Pharmaceuticals (NASDAQ: RVPH), ein Pharmaunternehmen in der späten Entwicklungsphase mit Schwerpunkt auf ZNS-, entzündlichen und kardiometabolischen Erkrankungen, hat ein geplantes öffentliches Angebot von Stammaktien und Optionsscheinen angekündigt. Das Angebot wird von A.G.P./Alliance Global Partners als alleinigem Platzierungsagenten verwaltet.
Das Unternehmen plant, die Erlöse zur Finanzierung von Forschungs- und Entwicklungsaktivitäten sowie für Betriebskapitalzwecke zu verwenden. Die Wertpapiere werden unter einer wirksamen Shelf-Registrierungserklärung bei der SEC angeboten. Die endgültige Größe, die Bedingungen und der Abschluss des Angebots hängen von den Marktbedingungen ab.
- Potential to strengthen the company's R&D pipeline and working capital
- Securities offered under an already effective shelf registration statement
- Potential dilution for existing shareholders
- Uncertainty regarding the final size and terms of the offering
Insights
Reviva's public offering signals potential dilution for shareholders as company seeks capital for R&D pipeline advancement.
Reviva Pharmaceuticals is pursuing a public offering of common stock and warrants in a move that signals capital needs for its late-stage CNS, inflammatory, and cardiometabolic pipeline. This financing approach typically dilutes existing shareholders, as new shares and potential warrant exercises increase the total share count while decreasing each investor's proportional ownership.
The offering structure - combining shares with warrants - suggests management is incentivizing participation by offering additional upside through the warrants, which is often necessary when raising capital from a position of relative weakness. While Reviva hasn't disclosed the specific offering size or price, investors should anticipate pricing below current market value to attract buyers, a standard practice in these scenarios.
The stated use of proceeds for R&D activities indicates Reviva likely needs additional capital to advance its clinical programs through critical development stages. For a late-stage pharmaceutical company, this funding is essential for completing clinical trials, regulatory submissions, and potential commercialization preparations. However, the inclusion of "working capital and general corporate purposes" suggests some funds may simply support ongoing operations rather than value-creating milestones.
The S-3 shelf registration (already effective since February 2024) gives the company flexibility to access the capital markets quickly when needed. A.G.P./Alliance Global Partners serving as the sole placement agent, rather than multiple underwriters in a syndicate, may reflect limited institutional interest or the relatively small size of the offering.
CUPERTINO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it intends to offer shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by Reviva. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
The Company currently intends to use the net proceeds from the offering to fund research and development activities and for working capital and other general corporate purposes.
The securities will be offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-276848), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 2, 2024, and declared effective by the SEC on February 13, 2024. A preliminary prospectus supplement will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying base prospectus, when available, may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering and uncertainties related to the size, timing, completion, and use of proceeds from the proposed offering. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s prospectus supplement to be filed with the SEC, and the documents incorporated by reference therein, including the Company’s Form 10-K for the year ended December 31, 2024 and Form 10-Q for the quarter ended March 31, 2025.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
REVIVA CONTACTS:
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com
FAQ
What is the purpose of RVPH's proposed public offering in June 2025?
Who is managing Reviva Pharmaceuticals' public offering?
What securities is RVPH offering in the June 2025 public offering?
When was RVPH's shelf registration statement declared effective?
What therapeutic areas does Reviva Pharmaceuticals focus on?
